News

Ribociclib is now licensed for use in Europe as a first-line treatment in combination with an aromatase inhibitor in postmenopausal women with hormone receptor positive, human epidermal growth

The bispecific monoclonal antibody is intended to be used as a once-weekly subcutaneous treatment for the disease to cover adults, adolescents and children. According to Roche, emicizumab binds

At 12 months, APL-2, administered monthly via intravitreal injection, showed a 29% (p=0.008) reduction in the rate of GA lesion growth compared to sham. With every other month

"New drugs like this one to treat advanced types of cancer are vital to ensure three in four people survive their disease by 2035.” – Dr Nigel Blackburn,

The study also did not meet its key secondary endpoints. Adverse events were generally balanced between Ace-ER and placebo and safety was consistent with previously released Ace-ER data.

Dravet Syndrome is a rare pediatric disease and lifelong form of epilepsy, which starts in the first year of life with frequent or prolonged seizures. Currently, the company

The results were reported by ViraCyte lead investigators at Baylor College of Medicine in the Journal of Clinical Oncology1.   Viralym-M is an "off-the-shelf", 3rd party T-cell product

Under the agreement, Grid has acquired the exclusive rights to all intellectual property, including relevant patents, related to Complement Factor H (CFH) antibodies as a cancer therapy, and

Both the compounds were discovered through the research collaboration between Zealand and Boehringer Ingelheim. According to Zealand, the glucagon/GLP-1 agonist activates two key gut hormone receptors GLP-1 and